Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29697466 | 1.00 | HPGDS (0.59) | HPGDSHTTCYP1A2CYP2C19PTGES | |
| SCHEMBL12850742 | 0.86 | HPGDS (0.47) | HPGDSHTTCYP1A2CYP2C19PTGES | |
| SCHEMBL14894589 | 0.79 | HPGDS (0.59) | HPGDSHTTCYP1A2CDC7 | |
| SCHEMBL21689072 | 0.79 | HPGDS (0.59) | HPGDSHTTCDC7MAOAALDH1A1 | |
| SCHEMBL4378912 | 0.79 | HPGDS (0.59) | HPGDSHTTCDC7ALDH1A1 | |
| SCHEMBL17460812 | 0.79 | HPGDS (0.64) | HPGDSCYP1A2BACE1ALDH1A1 | |
| SCHEMBL6183990 | 0.79 | HPGDS (0.59) | HPGDSHTTCYP1A2BACE1CDC7 | |
| SCHEMBL18703847 | 0.78 | HPGDS (0.55) | HPGDSHTTCDC7ALDH1A1NOS1 | |
| SCHEMBL29788946 | 0.76 | ALDH1A1 (0.57) | HPGDSCYP1A2BIRC5ALDH1A1 | |
| Water SCHEMBL27871202 | 0.76 | ALDH1A1 (0.57) | HPGDSCYP1A2BIRC5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092756-A1 | METHODS AND COMPOSITION FOR KRAS MODIFICATIONS | DUNAD THERAPEUTICS LTD. (GB) | 2024-03-21 | — | — | US | disclosed |
| EP-4247787-A2 | METHODS AND COMPOSITION FOR KRAS MODIFICATIONS | 2692372 Ontario, Inc. (CA) | 2023-09-27 | — | — | EP | disclosed |
| CN-116745264-A | Methods and compositions for KRAS modification | 2692372安大略公司 | 2023-09-12 | — | — | CN | disclosed |
| WO-2022106897-A2 | METHODS AND COMPOSITION FOR KRAS MODIFICATIONS | 2692372 ONTARIO, INC. (CA) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022106897-A2 | METHODS AND COMPOSITION FOR KRAS MODIFICATIONS | 2692372 ONTARIO, INC. (CA) | 2022-05-27 | — | — | WO | disclosed |
| CN-108064223-B | FXR (NR1H4) MODULATING COMPOUNDS CONTAINING HYDROXY GROUPS | 吉利德科学公司 | 2021-06-01 | — | — | CN | disclosed |
| EP-3233850-B1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2019-04-03 | — | — | EP | disclosed |
| EP-3233850-B1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2019-04-03 | — | — | EP | disclosed |
| CN-108064223-A | FXR (NR1H4) modulating compound of hydroxyl | 吉利德科学公司 | 2018-05-22 | — | — | CN | disclosed |
| EP-3233850-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20140194415-A1 | FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property (No2) Limite (GB) | 2014-07-10 | — | — | US | disclosed |
| EP-2744333-A1 | FATTY ACID SYNTHASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-06-25 | — | — | EP | disclosed |
| WO-2014008223-A2 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-09 | — | — | WO | disclosed |
| WO-2013177253-A2 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-11-28 | — | — | WO | disclosed |
| EP-2637660-A1 | FATTY ACID SYNTHASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-09-12 | — | — | US | disclosed |
| WO-2013052716-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013028447-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-02-28 | — | — | WO | disclosed |
| WO-2012064642-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-05-18 | — | — | WO | disclosed |
| US-6521618-B2 | Antineoplastic agents, agents for treatment of osteoporosis and polycystic kidney disease | WYETH | 2003-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092756-A1 | METHODS AND COMPOSITION FOR KRAS MODIFICATIONS | KRAS, NRAS, HRAS | HPGDS 1264/4885HTT 1082/4885CYP1A2 4743/4885 |
| US-20140194415-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS2, FADS1 | HPGDS 168/4885HTT 4551/4885CYP1A2 288/4885 |
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | HPGDS 191/4885HTT 3758/4885CYP1A2 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.